TGFBI and melanoma: Among the significant HLA I peptide ligand variants, we found CDKN2A P114L, ARL6IP6 R56L, GCA S80A, LOXL1 R141L, CFL1 L111F, HSPB1 I179N, and TGFBI E126K, which are a part of the melanoma-associated SAAV signature defined in this study.